Generic Veregen Availability
Last updated on Sep 11, 2024.
Veregen is a brand name of sinecatechins topical, approved by the FDA in the following formulation(s):
VEREGEN (sinecatechins - ointment;topical)
-
Manufacturer: ANI PHARMS
Approval date: October 31, 2006
Strength(s): 15% [RLD]
Has a generic version of Veregen been approved?
No. There is currently no therapeutically equivalent version of Veregen available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veregen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,858,662
Patent expiration dates:
- October 2, 2026✓✓
- October 2, 2026
-
Medicament for the treatment of viral skin and tumour diseases
Patent 9,770,406
Issued: September 26, 2017
Inventor(s): Chang Yunik & Lathrop Robert & Böhm Erwin & Gander-Meisterernst Irene & Greger Regina & Holldack Johanna & Moebius Ulrich
Assignee(s): Medigene AGThe invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a —[CH—(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH—[CH—(OH)][CH—R]- group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
Patent expiration dates:
- July 12, 2025✓✓
- July 12, 2025
More about Veregen (sinecatechins topical)
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anorectal preparations
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.